Bristol-Myers, Incyte to study PD-1/IDO1 combination
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Incyte initiated a research collaboration on 27 May to test Bristol-Myers' nivolumab and Incyte's INCB24360 in a Phase I/II clinical trial in both companies' ongoing quests to advance combinations that include their immunotherapy drug candidates.